Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0706 | 0.5 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.0706 | 0.5 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.0706 | 0.5 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0706 | 0.5 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0706 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0706 | 0.5 | 0.5 |
Plasmodium vivax | peptide deformylase, putative | 0.0706 | 0.5 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0706 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 30 uM | In vitro antitumor activity of the compound against HL60 (Human leukemia) cells. | ChEMBL. | No reference |
IC50 (functional) | > 30 uM | In vitro antitumor activity of the compound against HL60 (Human leukemia) cells. | ChEMBL. | No reference |
IC50 (functional) | > 40 uM | In vitro antitumor activity against L1210 (murine leukemia) cells. | ChEMBL. | No reference |
IC50 (functional) | > 40 uM | In vitro antitumor activity against L1210 (murine leukemia) cells. | ChEMBL. | No reference |
IC50 (functional) | = 54 uM | Antiviral activity against against herpes simplex virus-1. | ChEMBL. | No reference |
IC50 (functional) | = 83 uM | Antiviral activity against against herpes simplex virus-2. | ChEMBL. | No reference |
MIC (functional) | > 1 mM | Antibacterial activity against Escherichia coli MM 294 after 20 hrs by tube dilution method | ChEMBL. | 24900515 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.